secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001645113-24-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novocure reports preliminary 2023 revenue $509M (-5% YoY); NSCLC PMA submitted to FDA
--------------------------------------------------------------------------------

- Preliminary FY 2023 net revenues $509.3M, down 5% YoY on reduced US claim collections.
- Q4 2023 net revenues $133.8M, up 4% YoY; US contributed $91.3M, Germany $14.7M.
- 1,564 prescriptions in Q4 (+14% YoY); 3,755 active patients (+9% vs Q4 2022).
- PMA application for TTFields in NSCLC submitted to FDA/PMDA in December 2023.
- Appointed Dr. Nicolas Leupin as Chief Medical Officer effective Jan 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/0001645113-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511324000003/nvcr-20240108.htm
  HTML page:      https://secwatch.observer/filing/0001645113-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer